New Risk • 6h
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$1.5m net loss in 2 years). Share price has been volatile over the past 3 months (13% average weekly change). Revenue is less than US$5m (US$3.0m revenue). Market cap is less than US$100m (CA$15.7m market cap, or US$11.1m). Announcement • Mar 24
California Nanotechnologies Corp. announced that it has received CAD 0.9359 million in funding On March 23, 2026, the California Nanotechnologies Corp closed the transaction. In connection with the Offering, the Company has agreed to pay a cash commission in the aggregate of CAD 1,131.08 ($825) and to issue an aggregate of 154,179 common shares. A certain director of the Company subscribed for an aggregate of 500,000 Units under the Offering, New Risk • Mar 20
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CA$13.5m (US$9.85m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (CA$13.5m market cap, or US$9.85m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$1.5m net loss in 2 years). Revenue is less than US$5m (US$3.0m revenue). Announcement • Feb 25
California Nanotechnologies Corp. announced that it expects to receive CAD 0.75 million in funding California Nanotechnologies Corp announced a non-brokered private placement to issue 2,500,000 units at an issue price of CAD 0.30 for the proceeds of CAD 750,000 on February 24, 2026. Each Unit will be comprised of one common share and one Common Share purchase warrant. Each Warrant shall be exercisable to acquire one additional Common Share at an exercise price of CAD 0.41 ($0.30) for eighteen (18) months from the closing of the Offering. The Offering is subject to an over-allotment option allowing the Company to increase the Units sold by an additional 1,000,000 Units for additional proceeds of CAD 300,000, if fully exercised. The Offering is subject to the receipt of all necessary regulatory and other approvals, including the receipt of approval from the TSX Venture Exchange (the “TSXV”). Finder’s fees may be payable in connection with the Offering. Certain insiders of the Company may acquire securities under the Offering. New Risk • Feb 03
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$129k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$129k free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$1.5m net loss in 2 years). Revenue is less than US$5m (US$3.0m revenue). Market cap is less than US$100m (CA$15.3m market cap, or US$11.2m). Reported Earnings • Feb 01
Third quarter 2026 earnings released: US$0.023 loss per share (vs US$0.003 profit in 3Q 2025) Third quarter 2026 results: US$0.023 loss per share (down from US$0.003 profit in 3Q 2025). Revenue: US$392.5k (down 78% from 3Q 2025). Net loss: US$1.09m (down US$1.21m from profit in 3Q 2025). Revenue is forecast to grow 67% p.a. on average during the next 2 years, compared to a 7.9% growth forecast for the Machinery industry in Canada. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 133 percentage points per year, which is a significant difference in performance. New Risk • Jan 31
New major risk - Revenue and earnings growth Earnings have declined by 21% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 21% per year over the past 5 years. Minor Risks Revenue is less than US$5m (US$4.5m revenue). Market cap is less than US$100m (CA$16.8m market cap, or US$12.3m). Recent Insider Transactions Derivative • Oct 28
Interim CFO & Director exercised options to buy CA$252k worth of stock. On the 24th of October, Roger Dent exercised options to buy 637k shares at a strike price of around CA$0.25, costing a total of CA$159k. This transaction amounted to 29% of their direct individual holding at the time of the trade. Since March 2025, Roger's direct individual holding has increased from 2.37m shares to 2.53m. Company insiders have collectively bought CA$610k more than they sold, via options and on-market transactions, in the last 12 months. Reported Earnings • Oct 09
Second quarter 2026 earnings released: US$0.006 loss per share (vs US$0.015 loss in 2Q 2025) Second quarter 2026 results: US$0.006 loss per share (improved from US$0.015 loss in 2Q 2025). Revenue: US$779.9k (down 49% from 2Q 2025). Net loss: US$292.4k (loss narrowed 55% from 2Q 2025). Revenue is forecast to grow 29% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Machinery industry in Canada. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 143 percentage points per year, which is a significant difference in performance. Board Change • Sep 30
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Enrique Lavernia was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Sep 01
Board Member recently bought CA$315k worth of stock On the 28th of August, Christopher Melnyk bought around 2m shares on-market at roughly CA$0.20 per share. This transaction increased Christopher's direct individual holding by 2x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought CA$353k more in shares than they have sold in the last 12 months. Announcement • Aug 25
California Nanotechnologies Corp., Annual General Meeting, Oct 24, 2025 California Nanotechnologies Corp., Annual General Meeting, Oct 24, 2025. New Risk • Aug 21
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CA$13.2m (US$9.50m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (CA$13.2m market cap, or US$9.50m). Minor Risk Share price has been volatile over the past 3 months (13% average weekly change). Reported Earnings • Aug 01
First quarter 2026 earnings released: US$0.01 loss per share (vs US$0.016 profit in 1Q 2025) First quarter 2026 results: US$0.01 loss per share (down from US$0.016 profit in 1Q 2025). Revenue: US$716.6k (down 59% from 1Q 2025). Net loss: US$447.9k (down 164% from profit in 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has increased by 49% per year, which means it is well ahead of earnings. Recent Insider Transactions Derivative • Jul 21
Board Member exercised options to buy CA$102k worth of stock. On the 17th of July, Christopher Melnyk exercised options to buy 200k shares at a strike price of around CA$0.25, costing a total of CA$50k. This transaction amounted to 26% of their direct individual holding at the time of the trade. Since September 2024, Christopher's direct individual holding has increased from 776.46k shares to 976.46k. Company insiders have collectively bought CA$162k more than they sold, via options and on-market transactions, in the last 12 months. Recent Insider Transactions Derivative • Jul 20
Board Member exercised options to buy CA$108k worth of stock. On the 17th of July, Christopher Melnyk exercised options to buy 200k shares at a strike price of around CA$0.25, costing a total of CA$50k. This transaction amounted to 26% of their direct individual holding at the time of the trade. Since September 2024, Christopher's direct individual holding has increased from 776.46k shares to 976.46k. Company insiders have collectively bought CA$162k more than they sold, via options and on-market transactions, in the last 12 months. Reported Earnings • Jun 27
Full year 2025 earnings released: US$0.004 loss per share (vs US$0.011 profit in FY 2024) Full year 2025 results: US$0.004 loss per share (down from US$0.011 profit in FY 2024). Revenue: US$6.22m (up 87% from FY 2024). Net loss: US$158.3k (down 142% from profit in FY 2024). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 101% per year, which means it is well ahead of earnings. New Risk • Apr 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (CA$39.0m market cap, or US$27.9m). Reported Earnings • Jan 15
Third quarter 2025 earnings released: EPS: US$0.003 (vs US$0.016 in 3Q 2024) Third quarter 2025 results: EPS: US$0.003 (down from US$0.016 in 3Q 2024). Revenue: US$1.81m (up 56% from 3Q 2024). Net income: US$113.1k (down 78% from 3Q 2024). Profit margin: 6.3% (down from 44% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has increased by 96% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Oct 17
Second quarter 2025 earnings released: US$0.015 loss per share (vs US$0.007 profit in 2Q 2024) Second quarter 2025 results: US$0.015 loss per share (down from US$0.007 profit in 2Q 2024). Revenue: US$1.52m (up 122% from 2Q 2024). Net loss: US$655.0k (down 407% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has increased by 154% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Oct 09
Investor sentiment deteriorates as stock falls 26% After last week's 26% share price decline to CA$1.31, the stock trades at a trailing P/E ratio of 41.5x. Average trailing P/E is 33x in the Machinery industry in Canada. Total returns to shareholders of 1,441% over the past three years. Valuation Update With 7 Day Price Move • Sep 12
Investor sentiment improves as stock rises 26% After last week's 26% share price gain to CA$1.17, the stock trades at a trailing P/E ratio of 37.3x. Average trailing P/E is 25x in the Machinery industry in Canada. Total returns to shareholders of 1,200% over the past three years. Announcement • Aug 20
California Nanotechnologies Corp., Annual General Meeting, Oct 24, 2024 California Nanotechnologies Corp., Annual General Meeting, Oct 24, 2024. Valuation Update With 7 Day Price Move • Jul 16
Investor sentiment improves as stock rises 122% After last week's 122% share price gain to CA$1.02, the stock trades at a trailing P/E ratio of 30.1x. Average trailing P/E is 25x in the Machinery industry in Canada. Total returns to shareholders of 1,100% over the past three years. New Risk • Jul 12
New major risk - Financial position The company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (22% average weekly change). High level of non-cash earnings (155% accrual ratio). Minor Risks Shareholders have been diluted in the past year (31% increase in shares outstanding). Revenue is less than US$5m (US$4.6m revenue). Market cap is less than US$100m (CA$30.3m market cap, or US$22.2m). New Risk • Jun 30
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 11% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (11% operating cash flow to total debt). High level of non-cash earnings (197% accrual ratio). Minor Risks Shareholders have been diluted in the past year (39% increase in shares outstanding). Revenue is less than US$5m (US$3.3m revenue). Market cap is less than US$100m (CA$20.6m market cap, or US$15.1m). Reported Earnings • Jan 16
Third quarter 2024 earnings released: EPS: US$0.016 (vs US$0.002 in 3Q 2023) Third quarter 2024 results: EPS: US$0.016 (up from US$0.002 in 3Q 2023). Revenue: US$1.16m (up 177% from 3Q 2023). Net income: US$513.9k (up US$449.1k from 3Q 2023). Profit margin: 44% (up from 16% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 97% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth. Reported Earnings • Nov 01
Second quarter 2024 earnings released: EPS: US$0.007 (vs US$0.001 loss in 2Q 2023) Second quarter 2024 results: EPS: US$0.007 (up from US$0.001 loss in 2Q 2023). Revenue: US$685.9k (up 152% from 2Q 2023). Net income: US$213.7k (up US$240.2k from 2Q 2023). Profit margin: 31% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has only increased by 73% per year, which means it is significantly lagging earnings growth. Announcement • Oct 31
California Nanotechnologies Corp. announced that it has received CAD 1.5 million in funding On October 30, 2023, California Nanotechnologies Corp. closed the transaction. The company sold 10,000,000 Units which included full exercise of the over-allotment option, at a price of CAD 0.15 per Unit for the gross proceeds of CAD 1,500,000. Each Unit consists of one common share and one half of one Common Share purchase warrant. Each Warrant shall entitle the holder to acquire one additional Common Share at an exercise price of CAD 0.25 at any time on or before October 30, 2025. The Offering is subject to the receipt of all necessary regulatory and other approvals,including the receipt of final approval from the TSX Venture Exchange (the “TSXV”). Finder’s fees in the aggregate cash amount of CAD 22,673.50, equivalent to 5.5% of the gross proceeds of certain subscriptions under the Offering, were paid to eligible finders. No finder’s warrants or similar securities were issued in connection with the Offering. Eric Eyerman, Roger Dent, and Sebastien Goulet purchased an aggregate of 3,586,666 Units under the Offering, representing approximately 35.9% of the Offering. Buying Opportunity • Oct 10
Now 20% undervalued Over the last 90 days, the stock is up 5.3%. The fair value is estimated to be CA$0.25, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Meanwhile, the company has become profitable. Buying Opportunity • Sep 20
Now 22% undervalued Over the last 90 days, the stock is up 12%. The fair value is estimated to be CA$0.24, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Meanwhile, the company has become profitable. Announcement • Sep 15
California Nanotechnologies Corp. announced that it expects to receive CAD 1.25 million in funding California Nanotechnologies Corp has announced a non-brokered private placement of up to 8,333,333 units at a price of CAD 0.15 per Unit for total gross proceeds to the company of up to CAD 1,250,000 on September 14, 2023. The transaction included participation from Certain insiders and Eric Eyerman, Chief Executive Officer of the Company is also expected to participate in the Offering by purchasing 2,250,000 units at a price of CAD 0.15 per Unit for aggregate gross proceeds of CAD 333,333. Certain insiders of the Company may acquire securities under the Offering, with the expected Insider participation being at least 25% of the Offering. The transaction is subject to an over-allotment option allowing the company to increase the units sold by an additional 1,666,667 Units for additional proceeds of CAD 250,000, if fully exercised. Each Unit will be comprised of one common share in the capital of the Company and one half of one Common Share purchase warrant. Each Warrant shall be exercisable to acquire one additional Common Share at an exercise price of CAD 0.25 for two years from the closing of the Offering. The transaction is subject to the receipt of all necessary regulatory and other approvals, including the receipt of approval from the TSX Venture Exchange. The securities are expected to be immediately freely tradeable under applicable Canadian securities legislation if sold to purchasers resident in Canada, other than securities acquired by insiders which shall be subject to a hold period of four months pursuant to TSXV policies. Announcement • Sep 14
California Nanotechnologies Corp. Provides Earnings Guidance for the Ended August 31, 2023 California Nanotechnologies Corp. provided earnings guidance for the ended August 31, 2023. The company's revenues of approximately USD 675,000 are expected for the second quarter ended August 31, 2023. This is expected to represent another quarterly revenue record and a 148% increase over second quarter 2023 revenues of USD 271,969. The Company preliminary estimated net income of approximately USD 175,000 compared to a net loss of USD 26,496 for the same period last year. Buying Opportunity • Aug 20
Now 24% undervalued after recent price drop Over the last 90 days, the stock is down 2.7%. The fair value is estimated to be CA$0.24, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Meanwhile, the company has become profitable. Reported Earnings • Aug 01
First quarter 2024 earnings released: EPS: US$0.001 (vs US$0.002 in 1Q 2023) First quarter 2024 results: EPS: US$0.001 (down from US$0.002 in 1Q 2023). Revenue: US$509.3k (up 55% from 1Q 2023). Net income: US$35.5k (down 29% from 1Q 2023). Profit margin: 7.0% (down from 15% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has only increased by 48% per year, which means it is significantly lagging earnings growth. New Risk • Jul 01
New major risk - Financial position The company's interest payments are not well covered by earnings. Net interest cover: 1.7x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.7x net interest cover). Share price has been highly volatile over the past 3 months (26% average weekly change). Negative equity (-US$947k). Market cap is less than US$10m (CA$6.20m market cap, or US$4.68m). Minor Risks Profit margins are more than 30% lower than last year (5.8% net profit margin). Revenue is less than US$5m (US$1.4m revenue). Reported Earnings • Jun 30
Full year 2023 earnings released: EPS: US$0.003 (vs US$0.006 in FY 2022) Full year 2023 results: EPS: US$0.003 (down from US$0.006 in FY 2022). Revenue: US$1.38m (up 28% from FY 2022). Net income: US$79.8k (down 60% from FY 2022). Profit margin: 5.8% (down from 19% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has only increased by 63% per year, which means it is significantly lagging earnings growth. Announcement • Jun 24
California Nanotechnologies Corp., Annual General Meeting, Aug 23, 2023 California Nanotechnologies Corp., Annual General Meeting, Aug 23, 2023. Reported Earnings • Jan 31
Third quarter 2023 earnings released: EPS: US$0.003 (vs US$0.001 loss in 3Q 2022) Third quarter 2023 results: EPS: US$0.003 (up from US$0.001 loss in 3Q 2022). Revenue: US$1.02m (up 335% from 3Q 2022). Net income: US$88.6k (up US$108.3k from 3Q 2022). Profit margin: 8.7% (up from net loss in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 94% per year but the company’s share price has only increased by 63% per year, which means it is significantly lagging earnings growth. Reported Earnings • Nov 01
Second quarter 2023 earnings released: US$0.001 loss per share (vs US$0.001 loss in 2Q 2022) Second quarter 2023 results: US$0.001 loss per share (in line with 2Q 2022). Revenue: US$272.0k (up 62% from 2Q 2022). Net loss: US$26.5k (loss widened 14% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth. Announcement • Aug 13
California Nanotechnologies Corp., Annual General Meeting, Oct 11, 2022 California Nanotechnologies Corp., Annual General Meeting, Oct 11, 2022. Reported Earnings • Aug 03
First quarter 2023 earnings released: EPS: US$0.001 (vs US$0 in 1Q 2022) First quarter 2023 results: EPS: US$0.001 (up from US$0 in 1Q 2022). Revenue: US$329.2k (up 60% from 1Q 2022). Net income: US$50.3k (up US$60.0k from 1Q 2022). Profit margin: 15% (up from net loss in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has only increased by 30% per year, which means it is significantly lagging earnings growth. Buying Opportunity • Jul 28
Now 22% undervalued Over the last 90 days, the stock is up 6.7%. The fair value is estimated to be CA$0.10, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.1% over the last 3 years. Meanwhile, the company has become profitable. Reported Earnings • Jun 30
Full year 2022 earnings released: EPS: US$0.006 (vs US$0.004 loss in FY 2021) Full year 2022 results: EPS: US$0.006 (up from US$0.004 loss in FY 2021). Revenue: US$1.08m (up 36% from FY 2021). Net income: US$200.6k (up US$321.6k from FY 2021). Profit margin: 19% (up from net loss in FY 2021). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Reported Earnings • Feb 01
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: US$0.001 loss per share (vs US$0.001 loss in 3Q 2021). Revenue: US$234.6k (up 17% from 3Q 2021). Net loss: US$19.7k (loss narrowed 33% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings. Reported Earnings • Nov 03
Second quarter 2022 earnings released: US$0.001 loss per share (vs US$0.001 profit in 2Q 2021) The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2022 results: Revenue: US$168.2k (down 42% from 2Q 2021). Net loss: US$23.3k (down 215% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has increased by 30% per year, which means it is well ahead of earnings. Reported Earnings • Jul 01
Full year 2021 earnings released: US$0.004 loss per share (vs US$0.002 loss in FY 2020) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2021 results: Revenue: US$794.6k (down 4.4% from FY 2020). Net loss: US$121.0k (loss widened 116% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Reported Earnings • Jan 10
Third quarter 2021 earnings released: US$0.001 loss per share The company reported a poor third quarter result with weaker earnings, revenues and control over expenses. Third quarter 2021 results: Revenue: US$201.1k (down 15% from 3Q 2020). Net loss: US$29.6k (down 369% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Nov 02
First half earnings released Over the last 12 months the company has reported total losses of US$104.8k, with losses widening by 302% from the prior year. Total revenue was US$855.6k over the last 12 months, up 5.3% from the prior year. Announcement • Jul 07
California Nanotechnologies Corp. Auditor Raises 'Going Concern' Doubt California Nanotechnologies Corp. filed its Annual on Jun 29, 2020 for the period ending Feb 29, 2020. In this report its auditor, Meyers Norris Penny LLP - MNP LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern. 
